Familial Hyperlipidemia Type 2a


Familial hypercholesterolemia (FH) is an autosomal dominant disorder of lipid metabolism present from birth. It is characterized by very high low-density lipoprotein cholesterol (LDL-C) levels causing premature coronary heart disease. The majority of cases are undiagnosed and suboptimally treated. Early diagnosis and appropriate treatment are important in preventing premature death.[1][2][3][4]


Genetic disorders with high LDL-C are most commonly caused by autosomal dominant conditions and rarely, inherited as a recessive trait. Mutations in the LDL receptor (LDLR; “classic FH”) cause 80% to 90% of cases of clinical FH and have autosomal dominant inheritance. Rarely, mutations in APOB and PCSK9 can cause autosomal dominant hypercholesterolemia. The clinical phenotype cannot distinguish between these three mutations.

APOB synthesizes the major protein in LDL which is the ligand for LDLR, mutation resulting in defective ApoB-100 results in impaired binding of LDL particles to LDLR and thus impaired clearance. PCSK9 synthesizes a circulatory protein that limits LDL receptor lifespan, gain-of-function mutation results in FH.

Over 1500 mutations in the LDLR causing classic FH have been identified. Mutations can be homozygous or heterozygous. True homozygotes have the same mutation in both alleles, whereas compound heterozygotes have different mutations in each allele. Compound heterozygotes have a similar phenotype to homozygous FH.

It is important to note that about 30% to 50% of patients with FH phenotype do not have an identifiable gene defect, and thus, gene testing is not a requisite for the diagnosis which is in most cases clinical.

FH caused by a de novo mutation is very rare, and therefore, documenting a detailed family history is very important.


Heterozygous FH (HeFH) is one of the most common genetic disorders, occurring in approximately one in 200 to 500 people. Homozygous FH (HoFH) has a prevalence of one in 160,000 to 500,000 people. In patients with premature coronary artery disease, the prevalence of FH is much higher. The prevalence of FH is higher in Dutch Afrikaners, French Canadians, Ashkenazi Jews, Christian Lebanese, and some Tunisian groups. There is a “gene dosing effect,” and homozygotes are more severely affected than heterozygotes.


Normal number and function of LDL receptors in the liver is important for the uptake of LDL cholesterol. Receptor-negative FH patients have less than 2%, and receptor-defective patients have about 2% to 25% of normal LDLR activity. Reduced or absent uptake of LDL cholesterol by the liver leads to very high LDL cholesterol levels from birth with resultant premature atherosclerosis, critical aortic stenosis, and coronary artery disease (CAD). Homozygous FH patients often have untreated LDL-C levels above 500 mg/dL, but lower levels do not rule out HoFH. HoFH causes severe CAD by the first and second decade of life. Heterozygotes are also at increased risk of CAD between 30 to 60 years of age. Stroke is uncommon. Xanthomas, which are yellowish patches of cholesterol build up due to extremely high levels of LDL-C, can occur around eyelids (xanthelasma), within tendons of the elbows, hands, knees, and feet. In fact, a thickened Achilles tendon should raise a high level of suspicion for HoFH. The prevalence of xanthomas increases with age. Another diagnostic sign on the physical exam is corneal arcus which is a white, gray or blue opaque ring around the corneal margin when seen in individuals younger than 45 years of age.[5][6][7][8]

History and Physical

Detailed personal and family histories and a physical exam are important. Particular attention should be paid to atherosclerotic cardiovascular diseases (ASCVD) such as angina, prior myocardial infarction, arterial revascularization, transient ischemic attack, stroke, or claudication. Eliciting a history of other major risk factors for ASCVD is important, such as hypertension, smoking, obesity, diabetes, and chronic kidney disease. The physical exam should look for tendon xanthomas, xanthelasma, corneal arcus, evaluation of pulses of major arteries and signs of aortic stenosis.


It is important to exclude secondary causes of hypercholesterolemia such as hypothyroidism, nephrotic syndrome and liver disease by history and laboratory testing. Diagnosis of FH in most cases is:

  • Clinical, by personal history of early CAD, family history of premature CAD (definite MI or sudden death, at age younger than 55 in male first-degree relative or younger than 65 in female first-degree relative)
  • Through physical exam findings (tendon xanthomas and premature corneal arcus)
  • Elevated lipid levels (LDL-C greater than 190 mg/dL)

In the past, the diagnosis was usually made at the time of an acute MI in a young person. However, it is now most commonly found by routine lab testing that reveals elevated LDL-C which leads to clinical suspicion. Triglyceride levels are characteristically normal, and HDL levels might be low. It is important to emphasize that any LDL-C level greater than 190 mg/dL should trigger an investigation for HeFH or HoFH.

The diagnosis of FH in most cases is made phenotypically. Available clinical tools to make the diagnosis of FH are the Dutch Lipid Clinic Network criteria, Simon Broome criteria (Table 1), Make Early Diagnosis to Prevent Early Deaths (MED-PED) criteria, and Japanese FH criteria.[2][4][9][2]

Detection of index cases could be done by a targeted screening of individuals with premature CVD, opportunistic screening in primary care based on age and gender-specific plasma LDL-C levels, or universal screening based on age and gender-specific plasma LDL-C levels before the age of 20 years and ideally before puberty. Children with xanthomata or other physical findings of FH or suspected to have HoFH by family history should be screened at 2 years of age. Children suspected to have HeFH should be screened between ages of 5 and 10 years. It is recommended that 2 fasting LDL cholesterol values are obtained in children and adolescents. High probability of FH is indicated by LDL of greater than or equal to 155 mg/dL, or greater than or equal to 135 mg/dL with a parental history of hypercholesterolemia or premature CHD.

Testing should not be done during the acute illness because it can lower LDL-C levels leading to false negative testing. If already on statin therapy, it is important to look at pre-treatment values of LDL-C, if not available, the LDL-C level should be estimated based on the dose of the specific statin.

Cardiovascular risk assessment tools such Framingham risk score should not be used as FH is a lifetime coronary risk equivalent.

In asymptomatic patients with FH, cardiac CT and carotid ultrasound may be useful for stratifying risk and needs further studies.

Differential Diagnosis

In the differential diagnosis of hypercholesterolemia and premature atherosclerosis, familial combined hyperlipidemia, hyperapobetalipoproteinemia, familial dysbetalipoproteinemia, and polygenic hypercholesterolemia should be considered.

In the differential diagnosis of tendon xanthomas and premature atherosclerosis, rare genetic disorders such as sitosterolemia, and cerebrotendinous xanthomatosis should be considered.

Pearls and Other Issues

Cascade screening is a cost-effective, evidence-based intervention, starting with first-degree relatives of patients with FH by cholesterol screening with or without genetic testing. Use of genetic testing in cascade screening improves the detection rate of FH. Cascade screening can lead to early diagnosis and institution of therapy for FH resulting in ASCVD reduction. National and international organizations have recommended cascade screening for FH. Concerns regarding privacy require that the patient with FH make the first contact with family members. For patients diagnosed with FH, the Genetic Information Nondiscrimination Act protects against health insurance and employment discrimination.

Enhancing Healthcare Team Outcomes

The diagnosis and management of familial hypertriglyceridemia require an interprofessional team that includes an endocrinologist, primary care provider, nurse practitioner, gastroenterologist, cardiologist, an internist, and pharmacist. Besides pharmacological treatment in conjunction with a board-certified cardiology pharmacist consulting with clinical staff, it is important to advise patients on lifestyle modifications and to correct all modifiable non-cholesterol risk factors. A healthy diet, exercise therapy, smoking cessation and management of obesity is important.

In women of childbearing potential, counseling on contraception before starting a statin and pre-pregnancy counseling are important. Nursing staff can have involvement in this monitoring and counsel and inform the clinician of any changes in status. Statin therapy should be discontinued 3 months before planned conception and should not be used during pregnancy or breastfeeding. Lipid-lowering therapy other than bile acid sequestrants (Class B for pregnancy) should not be used during pregnancy. LDL apheresis has been safely used during pregnancy and is especially useful in patients with established CAD.

Orthotopic liver transplantation is considered for younger patients with HoFH with rapid progression of atherosclerosis or aortic stenosis if they are not able to tolerate LA or have inadequate LDL-C lowering with LA, diet, and medications.

(Click Image to Enlarge)
Simon Broome FH Register Diagnostic Criteria
Simon Broome FH Register Diagnostic Criteria
Contributed by Harsha Karanchi
Article Details

Article Author

Harsha Karanchi

Article Editor:

Kathleen Wyne


8/10/2020 4:00:07 PM



Gabčová D,Vohnout B,Staníková D,Hučková M,Kadurová M,Debreová M,Kozárová M,Fábryová Ľ,Staník J,Klimeš I,Rašlová K,Gašperiková D, The molecular genetic background of familial hypercholesterolemia: data from the Slovak nation-wide survey. Physiological research. 2017 Mar 31;     [PubMed PMID: 27824480]


Agabiti Rosei E,Salvetti M, Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. High blood pressure     [PubMed PMID: 27567901]


Klose G, [Introduction of PCSK9 inhibitors : New perspectives in treatment and practical implementation]. Herz. 2016 Jun;     [PubMed PMID: 27193908]


Ajufo E,Cuchel M, Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia. Current atherosclerosis reports. 2016 May;     [PubMed PMID: 26980316]


Bourbon M,Duarte MA,Alves AC,Medeiros AM,Marques L,Soutar AK, Genetic diagnosis of familial hypercholesterolaemia: the importance of functional analysis of potential splice-site mutations. Journal of medical genetics. 2009 May;     [PubMed PMID: 19411563]


Nauck MS,Köster W,Dörfer K,Eckes J,Scharnagl H,Gierens H,Nissen H,Nauck MA,Wieland H,März W, Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia. Human mutation. 2001 Aug;     [PubMed PMID: 11462246]


Kawasuji M,Sakakibara N,Fujii S,Yasuda T,Watanabe Y, Coronary artery bypass surgery with arterial grafts in familial hypercholesterolemia. The Journal of thoracic and cardiovascular surgery. 2000 May;     [PubMed PMID: 10788822]


Lauer RM, Role of family history and family testing in cardiovascular risk assessment. The American journal of medicine. 1999 Aug 23;     [PubMed PMID: 10484231]


Ojala JP,Helve E,Karjalainen K,Tarkkanen A,Tikkanen MJ, Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. Atherosclerosis. 1990 May;     [PubMed PMID: 2360923]